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Abstract
Recent genome- and epigenome-wide studies demonstrate that the DNA methylation is controlled in part by genetics,
highlighting the importance of integrating genetic and epigenetic data. To better understand molecular mechanisms
affecting gene expression, we used the candidate susceptibility gene paraoxonase 1 (PON1) as a model to assess associations
of PON1 genetic polymorphisms with DNA methylation and arylesterase activity, a marker of PON1 expression. PON1 has
been associated with susceptibility to obesity, cardiovascular disease, and pesticide exposure. In this study, we assessed
DNA methylation in 18 CpG sites located along PON1 shores, shelves, and its CpG island in blood specimens collected
from newborns and 9-year-old children participating (n¼449) in the CHAMACOS birth cohort study. The promoter
polymorphism, PON1-108, was strongly associated with methylation, particularly for CpG sites located near the CpG island
(P << 0.0005). Among newborns, these relationships were even more pronounced after adjusting for blood cell composition.
We also observed significant decreases in arylesterase activity with increased methylation at the same nine CpG sites at
both ages. Using causal mediation analysis, we found statistically significant indirect effects of methylation (b(95%
confidence interval): 6.9(1.5, 12.4)) providing evidence that DNA methylation mediates the relationship between PON1-108
genotype and PON1 expression. Our findings show that integration of genetic, epigenetic, and expression data can shed light
on the functional mechanisms involving genetic and epigenetic regulation of candidate susceptibility genes like PON1.
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Background
Epigenetic modifications, including DNA methylation, chroma-
tin modifications, and non-coding RNAs, are heritable and
affect gene expression without a change in DNA sequence [1, 2].
Because of their impact on gene expression, there is a growing
recognition that epigenetics may play an important role in key
biological processes and mechanisms of disease development
[3–5]. DNA methylation is an important epigenetic mechanism
and is also the most commonly measured epigenetic mark.
Available methodologies for the measurement of DNA
methylation are relatively high throughput and cost-effective,
allowing for its use in population studies. Interest in DNA meth-
ylation has grown rapidly in recent years resulting in the publi-
cation of numerous studies examining associations of DNA
methylation with environmental exposures as well as adverse
health outcomes in human populations [6–9].
In genetic epidemiology, concepts of genetic architecture
such as the existence of haplotype blocks and linkage disequi-
librium (LD) transformed the way in which genetic association
studies were designed, analyzed, and interpreted [10].
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Epigenome-wide data emerging from recent studies are now
providing analogous information on the methylome that can
further inform epigenetic analysis for population studies. For
instance, relationships of methylation at CpG sites in the same
gene are often performed as one CpG site at a time. However, re-
cent studies have shown that methylation at nearby CpG sites
can be highly correlated with each other, although over shorter
distances than observed with single-nucleotide polymorphisms
(SNPs) in the genome [11, 12]. Furthermore, methylation may be
partially controlled by genetics [11, 12]. Therefore, to under-
stand the molecular mechanisms explaining how DNA methyl-
ation can affect health through gene expression changes, it will
be important in population studies to integrate data on DNA
methylation with data on genetic polymorphisms and gene ex-
pression [13, 14].
Here, we use paraoxonase 1 (PON1) as a model for integrating
different types of molecular data that can be used to understand
the role of epigenetics on gene expression. PON1 is a multifunc-
tional enzyme involved in oxidant defense [15], and its genetic
variants and lower levels have been linked to adverse health out-
comes including adverse neurodevelopment, cardiovascular dis-
ease, and obesity [16–22]. We previously studied PON1 variability
in Mexican-American children and their mothers from the Center
for Health Assessment of Mothers and Children of Salinas
(CHAMACOS) birth cohort and found a much larger than previ-
ously known (>100-fold) range of levels and substrate-specific ac-
tivities defined in part by age and genotype [23, 24]. This broad
variability of PON1 within populations suggests differential sus-
ceptibility among individuals. PON1 sequencing and haplotype
analyses in this cohort have shown that the PON1 promoter poly-
morphism (PON1-108; rs705379) is the strongest known predictor
of PON1 gene expression and protein levels. Even so, it explains
less than 25% of the variability of PON1 protein levels; further-
more, incorporation of other genetic variants explained <3% of
additional variability. This means that other factors beyond
genetics, including epigenetics, may contribute to modulation of
PON1 gene expression.
There are a total of 287 CpG sites located in the PON1 gene
including one CpG island in the promoter region comprising 19
CpG sites (Fig. 1). Beyond the CpG island, there are an additional
66, 48, and 146 CpG sites within shores, shelves, and open sea
regions, respectively. One recent study showed that a PON1 SNP
located in a miRNA binding site (miR-616) was associated both
with changes in PON1 expression and increased risk of ischemic
stroke and carotid atherosclerosis [25]. These data underscore
the vital influence of epigenetic marks like miRNA and DNA
methylation on PON1 and demonstrate further the clinical sig-
nificance of PON1 variability [26]. To our knowledge, few studies
of PON1 epigenetics in relation to molecular phenotype have
been reported [27, 28].
The purpose of this study is to determine the relationship of
DNA methylation in the PON1 gene with PON1 genetic polymor-
phisms and with gene expression at the protein level in
CHAMACOS children. In addition to expanding molecular char-
acterization of PON1 variability to epigenetics, our data can
serve as a model for integrating genetic, epigenetic, and expres-
sion data on candidate susceptibility genes.
Results
PON1 CpG Sites
We used the data from a 450K BeadChip array to assess CpG
sites located in the PON1 gene in blood specimens collected
from 449 children. Samples were assessed at two time points,
once at birth (n¼ 378) and again at the age of 9 years (n¼ 247).
The 450K Bead Chip array included 18 of the 287 PON1 CpG sites,
which are described in Table 1 and shown in Fig. 1. The majority
of CpG sites interrogated were located in the promoter region
and included several sites in the CpG island (n¼ 4), shores
(n¼ 9), and shelves (n¼ 1).
PON1Methylation
Levels of DNA methylation in newborns and 9-year-old children
are shown graphically in Fig. 2. At both ages, average methyla-
tion levels (expressed as M values, see Methods) ranged from
2.1 to 3.4 among sites (Sites 1–4 and 14–16) that were further
away from the transcription start site (TSS) and were much
lower (0.03–2.11) among sites closer in proximity to the TSS
(Sites 5–13). At the majority of individual CpG sites, methylation
levels were slightly higher at the age of 9 years; these differ-
ences by age were no longer statistically significant after adjust-
ing for cell composition in generalized estimating equation
models with the exception of one CpG site (Site 4, cg 24062571).
For Site 4, we observed slightly higher methylation at the age of
Figure 1. CpG sites and SNPs in the PON1 gene. This map of PON1 spans chromosome 7 from coordinates 94 927 671 to 94 941 000 in (A) and 94 941 000 to 94 955 500 in (B).
It shows all 287 CpG sites and the subset of CpG sites included in the 450K BeadChip assay. There is one CpG island in the non-coding region (B) and the distribution of
SNPs across the gene is also shown
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9 years, and this difference persisted after adjusting for cell
composition.
It is well documented in genetic epidemiology that SNPs in
close proximity to each other are highly correlated with each
other, forming LD blocks that tend to be inherited together [10].
Although less is known about epigenetic architecture, there is a
growing understanding that nearby CpG sites may also be corre-
lated with each other [11, 12]. Therefore, we examined correla-
tions among PON1 CpG sites in newborns and in 9-year olds
(Fig. 3). Among CpG sites in umbilical cord blood, we identified
two methylation blocks (see Methods for definition) containing
clusters of highly correlated sites (Fig. 3A). Block 1 contained
sites in close proximity to the TSS (Sites 5–13) and spanned 350
base pairs; we will refer to this as the central cluster of PON1
CpG sites or Block 1. Correlation coefficients (r) for CpG site pairs
in Block 1 ranged from 0.53 to 0.98. Block 2 (Sites 14–16) spanned
1000 base pairs in length and correlation coefficients ranged
from 0.55 to 0.85. Interestingly, sites from Block 2 were also
correlated with Sites 1–4 (r ranged from 0.42 to 0.88), and we
subsequently refer to these sites (Block 2 and Sites 1–4) as the
outer cluster of CpG sites. Among 9-year-old children (Fig. 3B),
we observed only one block consisting of Sites 5–13 with corre-
lation coefficients ranging from 0.76 to 0.98. Although sites were
again correlated with each other among Sites 14–16, their corre-
lations were not high enough to meet the definition of a meth-
ylation block (r2< 0.4 for most CpG site pairs).
Relationships of PON1 Genotype with PON1Methylation
In agreement with other studies [29, 30] we previously found
the promoter polymorphism at position -108 (PON1-108) to be the
most significant predictor of PON1 expression as measured by
arylesterase (AREase) activity in the CHAMACOS cohort [24, 31].
As methylation can also affect gene expression, we examined
whether this promoter SNP was associated with methylation at
the 16 CpG sites assessed in CHAMACOS newborns and 9-year
olds. Figure 3 shows the differences in methylation by PON1-108
genotype. The methylation density plots demonstrate little to
no difference in methylation in the outer cluster sites (Fig. 4A
and C). However, among sites in methylation Block 1 (Fig. 4B),
there is a clear separation by genotype, providing evidence of al-
lele-specific methylation (ASM). Those with the CC genotype,
which has been associated with higher levels of gene expres-
sion [30], had the lowest levels of methylation, whereas those
with the CT genotype had intermediate levels of methylation
and those with TT genotypes had the highest levels of methyla-
tion. Furthermore, variance was larger within the TT group
compared with the CT and CC groups. Similar patterns were ob-
served in 9-year-old children (data not shown).
Regression models of PON1-108 genotype with methylation
(Table 2) also showed the same trends. We found very strong
positive associations of the number of PON1-108 T alleles with
methylation levels, particularly those in methylation Block 1
(P values ranged from 1.34E-11 to 2.73E-30). For instance, on av-
erage, children with the CT genotype had methylation M values
that were 0.63 units higher than CC kids at CpG Site 8 located in
the CpG island. These associations remain significant even after
Bonferonni correction for multiple testing. For Block 1 sites, the
variation of methylation explained by PON1-108 genotype as de-
termined by r2 of the regression models ranged from 17 to 39%
in cord bloods. As methylation profiles can differ by cell type in
Table 1. Summary of PON1 CpG sites assessed by 450K Beadchip
CpG site
number
Illumina
450K ID Coordinatesa
Relation to
CpG island
Distance from
PON1-108 SNP
1 cg22798737 94 927 713 Open sea 26 188
2 cg01879893 94 928 193 Open sea 25 709
3 cg09416203 94 928 249 Open sea 25 652
— cg05433222b 94 948 020 Open sea 5881
4 cg24062571 94 950 658 N_Shelf 3244
5 cg07404485 94 953 654 N_Shore 248
6 cg05342682 94 953 680 N_Shore 221
7 cg04155289 94 953 771 Island 131
8 cg19678392 94 953 811 Island 91
9 cg21856205 94 953 878 Island 24
10 cg17330251 94 953 956 Island 55
11 cg01874867 94 954 059 S_Shore 158
12 cg20119798 94 954 144 S_Shore 243
13 cg04871131 94 954 202 S_Shore 301
14 cg23055772 94 954 438 S_Shore 537
15 cg07809369 94 954 455 S_Shore 554
— cg17020263b 94 955 053 S_Shore 1152
16 cg15887283 94 955 348 S_Shore 1447
aReference hg 19, Chromosome 7.
bThese CpG sites contained SNPs, so their methylation data were not included.
A B
Figure 2. Methylation box plots in newborns (n ¼ 378) and 9-year-old (n¼247) children. DNA methylation was measured using 450K BeadChip. The box plots show
methylation levels at 16 CpG sites in the PON1 gene in (A) umbilical cord blood and (B) 9-year-old blood. CpG site numbers correspond to those listed in Table 1
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Figure 3. Correlation plots of PON1 CpG sites in (A) umbilical cord blood and (B) 9-year-old blood. The colors of the squares represent the correlation between CpG sites
(r). Squares are white/yellow if CpG sites are not correlated (r¼ 0) and red if they are strongly correlated (r  1). Similar to the concept of LD between SNPs, CpG sites
within close proximity of each other tend to be correlated with each other. Here, we identified two methylation blocks (Sites 5–13 and 14–16) where methylation levels
were strongly correlated with each at both ages. Block 1 is referred to as the inner cluster of CpG sites, whereas Sites 1–4 and 14–16 are referred to as the outer cluster
of CpG sites. CpG site numbers correspond to those listed in Table 1
Figure 4. Methylation density plots by PON1-108 genotype (CC-pink CT – green TT –purple). Each plot shows density by methylation M-value at eight different CpG sites,
from different regions of PON1. Plots in Row A are CpG Sites 1 and 4, respectively. Plots in Row B are from methylation Block 1 (Sites 5, 8, 11, and 13). Plots in Row C
show Sites 14 and 16 from methylation Block 2. We include plots from just a few CpG sites that are representative of other CpG sites in the same region. Among
CHAMACOS newborns with methylation data (n¼271), 83 were CC, 138 were CT, and 50 were TT. Sites from methylation Block 1 show a distinct separation by PON1-108
genotype
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blood, we also examined the relationship of PON1-108 genotype
adjusting for cell composition in a subset of 82 newborns with
differential cell count data (Supplementary Table S1). Results
were very similar to unadjusted models; however, the variance
of methylation explained by PON1 genotype doubled for Block 1
sites (38–76%). The same but even stronger trends were also
seen in 9-year-old children (P values for Block 1 sites ranged
from 6.28E-33 to 7.55E-50 and r2 ranged from 0.43 to 0.68); mod-
els adjusting for cell composition were very similar to unad-
justed models (Table 2 and Supplementary Table S1).
Beyond the PON1-108 SNP, we also examined associations of
PON1 methylation sites with an additional panel of 40 SNPs and
indels distributed throughout the PON1 gene and 4 SNPs located
in PON2 and PON3 in a smaller subset of 214 newborns and 157
9-year-old children (Supplementary Tables S2 and S3). As ex-
pected, methylation in Block 1 CpG sites were associated with
additional SNPs located in the promoter region. These SNPs
were all in strong LD with PON1-108. We also observed weaker but
significant associations of several other SNPs with methylation
of Block 1 CpG sites, including several located further
downstream (>2 kb) of PON1 in the PON2 and PON3 genes and
two SNPs that were in strong LD with PON155, a common coding
SNP.
Relationships of PON1Methylation with
AREase Activity
Using AREase as a marker of gene expression at the protein level,
we examined associations of PON1 methylation at each of the 16
CpG sites with AREase activity (Fig. 5A, Supplementary Table S4).
At both ages, methylation at individual Block 1 CpG sites was sig-
nificantly associated with AREase activity, and this relationship
was noticeably stronger at the age of 9 years (Table 2, Fig. 5B). This
may be due to the higher mean, range, and variance of AREase ac-
tivity observed in 9-year-old children compared with newborns
who have very low levels of PON1 protein levels at birth. Effects of
cell composition may also contribute to this difference. After ad-
justment for cell composition in a subset of cord bloods, we ob-
served trends in the same direction but the magnitude of the
associations increased and P values were decreased. Results were
Figure 5. Relationship of methylation with AREase activity. The plot shows regression P values for modelling the association of methylation at each individual CpG Site
with AREase activity in (A) newborns and (B) 9-year olds. The solid line indicates a P value of 0.05 and the dotted line represents a P value of 0.01
Table 2. Association of PON1-108 genotype
a with DNA methylation in blood in newborns and 9-year olds
Newborns 9-Year Olds
CpG Site CpG site id Relation to island N Beta (95% CI) P N Beta (95% CI) P
1 cg22798737 Open sea 271 0.06(0.14,0.03) 0.20 218 0.00(0.07,0.06) 0.97
2 cg01879893 Open sea 271 0.04(0.12,0.03) 0.23 218 0.00(0.07,0.07) 0.90
3 cg09416203 Open sea 271 0.08(0.15, 0.01) 0.03 218 0.03(0.11,0.05) 0.42
4 cg24062571 N_Shelf 271 0.05(0.12,0.02) 0.18 218 0.01(0.07,0.06) 0.86
5 cg07404485 N_Shore 271 0.32(0.24,0.39) 8.28E-15 218 0.51(0.45,0.58) 6.58E-37
6 cg05342682 N_Shore 271 0.32(0.25,0.40) 5.00E-15 218 0.52(0.45,0.58) 5.54E-35
7 cg04155289 Island 271 0.33(0.24,0.42) 1.34E-11 218 0.59(0.51,0.67) 6.28E-33
8 cg19678392 Island 271 0.63(0.54,0.73) 4.13E-30 218 0.92(0.82,1.02) 5.73E-45
9 cg21856205 Island 271 0.26(0.22,0.30) 2.73E-30 218 0.35(0.31,0.39) 4.71E-46
10 cg17330251 Island 271 0.63(0.52,0.74) 2.15E-25 218 0.95(0.85,1.04) 4.56E-48
11 cg01874867 S_Shore 271 0.59(0.49,0.69) 8.59E-25 218 0.92(0.82,1.01) 7.55E-50
12 cg20119798 S_Shore 271 0.38(0.30,0.47) 2.14E-16 218 0.69(0.61,0.77) 3.77E-40
13 cg04871131 S_Shore 271 0.26(0.17,0.34) 8.04E-09 218 0.52(0.44,0.61) 1.55E-24
14 cg23055772 S_Shore 271 0.01(0.06,0.05) 0.76 218 0.00(0.05,0.05) 0.86
15 cg07809369 S_Shore 271 0.05(0.04,0.13) 0.31 218 0.20(0.12,0.28) 1.29E-06
16 cg15887283 S_Shore 271 0.06(0.14,0.03) 0.18 218 0.02(0.09,0.05) 0.64
CI, confidence interval.
aPON1-108 genotype was coded as 0, 1, and 2 T alleles for CC, CT, and TT children, respectively.
PON1 epigenetics | 5
essentially unchanged in 9-year-old children suggesting that the
influence of cell composition on these associations was much
stronger in cord blood (Supplementary Table S5).
To consider the methylation at multiple correlated CpG sites
in one model, we also used PCs analysis. Two PCs explained
>95% of the variability of methylation in Block 1, and these PCs
were included in the models of AREase activity (Table 3). Both
PCs describing cord blood methylation from Block 1 (PC1-1 and
PC1-2) were significantly associated with cord AREase activity.
In 9-year-old children, only PC1-1 was significantly associated
with AREase activity.
Mediation of PON1-108 Genotype on AREase Activity by
PON1Methylation
Because PON1-108 was the SNP most strongly associated with
methylation and expression and prior studies suggest epige-
netics can at times mediate effects of genetics on expression,
we used the PARAMED module [32, 33] to determine to what ex-
tent PON1 methylation mediates the effects of PON1-108 geno-
type on AREase activity (Table 4). PARAMED relies on causal
inference methodologies to estimate the natural direct effect
and NIE in the presence of exposure-mediator interactions. We
limited this analysis only to the PCs that were significantly as-
sociated with AREase activity (PC1-1 and 2 for newborns and
PC1-1 for 9-year olds). Among newborns, there was a significant
interaction between PON1 genotype and both PCs of Block 1
methylation. Furthermore, the NIE of the first PC of Block 1
methylation (PC1-1) on expression was statistically significant
(b(95% confidence interval)¼ 6.91(1.45,12.37); P¼ 0.013) provid-
ing evidence that methylation in Block 1 mediates the effect of
PON1-108 genotype on AREase activity. The NIE for PC1-2 was not
statistically significant, suggesting that some portion of the re-
lationship between PON1-108 genotype and AREase is not driven
by methylation. Among 9-year olds, we did not observe a signifi-
cant interaction of genotype and methylation on AREase activ-
ity. Additionally, the NIE for PC1-1 did not reach statistical
significance. Overall, our mediation analyses suggest that at
least in newborns, PON1 methylation in Block 1 mediates the as-
sociation of PON1-108 genotype on AREase activity.
Discussion
In this study, we used PON1 as a model for integration of genetic
and epigenetic data and their relationship with gene expres-
sion. We expanded our molecular studies of PON1 to DNA
methylation at 16 CpG sites in a large cohort of young Mexican-
American children from the Salinas Valley, CA. We found
evidence of allele-specific methylation between the PON1-108
SNP and methylation sites belonging to methylation Block 1
surrounding the promoter region, demonstrating a genetic con-
tribution to DNA methylation. Furthermore, methylation levels
at this Block 1 were strongly associated with AREase activity, a
measure of PON1 protein quantity in blood. Mediation analyses
provided evidence that methylation can act as a mediator of the
PON1-108 SNP on AREase activity
To our knowledge, only one other study has examined asso-
ciations of PON1 methylation with AREase activity. Similar to
our results, de la Iglesia et al. [28] also reported an inverse rela-
tionship between methylation at CpG Sites 5–8 and AREase ac-
tivity in white blood cell specimens collected from 47 obese
adults. Our study, relying on a much larger sample size (n¼ 449)
demonstrated that similar relationships also exist at birth and
during childhood and found that some of these relationships
may be driven by genetics.
Few if any studies that have focused on PON1 have exam-
ined associations of genetic polymorphisms with PON1 methyl-
ation. However, we were able to extract publicly available data
on PON1 from a handful of studies that have taken genome-
and epigenome-wide approaches to explore patterns of methyl-
ation and relationships with genetics. The same methylation
block that we identified in CHAMACOS children (Sites 4–12,
Block 1) was also identified as a methylation cluster in two
other studies, one a study of whole blood specimens from
adults (n¼ 247) and the other a smaller study of fetal (n¼ 14)
and adult (n¼ 181) liver samples [11, 34]. In line with our find-
ings, the study of liver specimens demonstrated inverse
Table 3. PCs regression models of DNA methylation in blood with AREase activity in children
Newbornsa 9-Year oldsa
estimate SE P r2 estimate SE P r2
Block 1 CpG sites pc1-1 1.31 0.62 0.035 5.84 1.09 2.78E-07
pc1-2 8.19 2.61 0.002 0.06 8.20 6.10 0.181 0.15
SE, standard error.
aThe newborn model examines association of cord blood methylation with cord AREase activity. The 9-year model examines the association of 9-year-old blood meth-
ylation with 9-year AREase activity.
Table 4. Mediation analysis: total, direct, and indirect effect
Newborns 9-Year olds
PC1-1 PC1-2 PC1-1
Estimate (95% CI) P Estimate (95% CI) P Estimate (95% CI) P
Total effect 16.3(22.1, 10.5) <0.0005 15.6(21.5, 9.7) <0.0005 30.6(42.9, 18.3) <0.0005
Natural direct effect 23.2(30.8, 15.6) <0.0005 19.1(26.3, 11.9) <0.0005 15.6(35.3,4.19) 0.123
NIE 6.9(1.5,12.4) 0.013 3.5(1.8,8.9) 0.195 15.0(30.9,0.83) 0.063
CI, confidence interval.
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correlations between PON1 methylation at Sites 4–12 and PON1
gene expression (mRNA) [34] and also observed significant asso-
ciations of PON1-108 genotype with methylation at the same
sites. Our study showed that similar relationships can be ob-
served in children’s blood specimens and when we consider
PON1 expression at the protein level (AREase activity)—the final
step of the flow of genetic information described in the central
dogma of molecular biology.
There is growing interest in the phenomenon of ASM such
as that observed between PON1 methylation in the promoter re-
gion and PON1-108 genotype. ASM is a hallmark feature of im-
printed genes but recent epigenome-wide studies have shown
that the most prevalent types of ASM are those where genotype
affects DNA methylation in cis among non-imprinted genes
[12, 35, 36]. A recent study in blood specimens reported a preva-
lence of ASM that was cis in nature in 8.1% of heterozygous
SNPs and that 22% of the genes exhibiting ASM also displayed
allele-specific gene expression, as we observed with PON1 [36].
ASM is a particularly interesting phenomenon because it pro-
vides a functional link between genetic polymorphisms and
phenotypic differences beyond nonsynonymous SNPs in coding
regions [35]. Furthermore, it has been suggested that regions
characterized by ASM may be more susceptible to environmen-
tal influences [37].
Mechanisms regulating methylation patterns in promoter re-
gions are not well understood although several models through
which regulation may occur have recently been proposed [38].
The strong association of the PON1-108 genotype with both meth-
ylation and expression is particularly interesting because it serves
as an example of genetic regulation of methylation and expres-
sion at a transcription factor binding site. Previous studies have
demonstrated that this polymorphism is located in a specificity
protein 1 (Sp1) binding site [30, 39], which likely activates tran-
scription via methylation. Sp1 binding blocks DNA methyltrans-
ferases (DNMTs) from accessing the promoter, leading to lower
methylation levels and thus more transcription [38, 40]. The Sp1
binding site at position 108 can be disrupted by the T allele, which
in CHAMACOS children was associated both with increased
methylation levels and lower expression as measured by AREase
activity. Furthermore, results from our mediation analyses sug-
gest that the effect of the PON1-108 polymorphisms on expression
is mediated in part by methylation at methylation Block 1.
Although we observed very strong associations between the
PON1-108 genotype, DNA methylation, and AREase activity in a
large cohort of CHAMACOS children, this study has some limita-
tions. We used AREase activity, a measure of protein levels in
blood, as a proxy for gene expression. It is possible, however,
that AREase may be more reflective of liver expression as PON1
present in plasma is primarily synthesized in the liver [41].
Relationships observed between blood methylation and AREase
activity were strikingly similar to those reported between meth-
ylation and mRNA expression in blood and liver samples, possi-
bly because ASM events may not be tissue specific. One study
recently observed a concordance of ASM between tissue types
and hypothesized that this may be due either to “shared gene
regulatory events that occur early in development or an inher-
ent property of DNA sequence that directly affects the propen-
sity of DNA methylation” [36]. Additionally, as the 450 K
BeadChip array assays only a select number of CpG sites
throughout the methylome, we were only able to interrogate 18
of the 287 CpG sites located in the PON1 gene. Although the cov-
erage of sites in and around the promoter region was quite
good, future studies would benefit from a more complete as-
sessment of the PON1 CpG sites across the entire gene using a
higher resolution methodology like MethylSeq. Another poten-
tial source of bias is related to missingness of biological speci-
mens, which is common in cohort studies utilizing pediatric
blood samples. Only 65–71% of participants included in this
study had adequate blood volumes for AREase analysis. This
could limit generalizability of the relationships that we ob-
served. When we compared children included in our study with
all other children in the cohort, however, we did not find that
they differed by significant demographic or exposure factors.
Finally, our data on differential cell count in cord blood speci-
mens were limited to only a subset of participants. It is still pos-
sible that some amount of residual confounding was not
accounted for in the models that did not adjust for cell composi-
tion. Since adjusting for cell composition did not substantially
change results, however, the unmeasured residual confounding
is likely small.
Conclusions
Recent genome- and epigenome-wide studies are providing
new data showing emerging patterns of a complex interplay be-
tween genetics and epigenetics on gene expression that may af-
fect health [11, 12]. Here, we applied some of the new
understanding of epigenomic architecture, relationships with
genetic polymorphisms, and mediation analysis using PON1 as
a model. We found strong evidence of ASM between the pro-
moter polymorphism PON1-108 and methylation in a cluster of
CpG sites surrounding the TSS that was also associated with
PON1 protein levels. Our results demonstrate that integrating
genetic, epigenetic, and expression data can provide evidence of
functional mechanisms involving genetic and epigenetic regu-
lation of candidate susceptibility genes.
Methods
Study Subjects
The CHAMACOS study aims to examine the effects of pesticides
and other environmental exposures in a population of pregnant
women and children living in the agricultural Salinas Valley,
CA. Women were eligible for enrollment if they were at least 18
years of age, at less than 20 weeks’ gestation, Spanish or English
speaking, eligible for low-income health insurance, receiving
prenatal care at one of the local community clinics, and plan-
ning to deliver at the public hospital. Six hundred and one preg-
nant women were enrolled in 1999–2000 and 526 delivered live
born singleton newborns [42]. CHAMACOS women were inter-
viewed by bilingual, bicultural interviewers near the end of the
first (13 weeks’ gestation) and second (26 weeks’ gestation)
trimesters of pregnancy. Information was obtained on sociode-
mographic characteristics, mother’s reproductive and medical
history, prenatal lifestyle exposures, diet, occupational and resi-
dential history, exposures to pesticides and other environmen-
tal chemicals, and housing quality.
Methylation of PON1 CpG sites was measured in blood sam-
ples collected from children at delivery (umbilical cord blood
representing fetal blood) and when they were 9-year old
(mean6SD¼ 9.360.3 years). Our study sample included a total
of 449 children who had DNA samples available for PON1 geno-
typing in addition to methylation analysis at birth and/or at the
age of 9 years. Of these children, 176 had samples available at
both time points, 202 had samples only at birth, and 71 had
samples at the age of 9 years only. Furthermore, among those
children with DNA samples available, 247 and 176 had adequate
PON1 epigenetics | 7
blood volumes available for analysis of arylesterase (AREase) ac-
tivity at birth and age of 9 years, respectively.
For both time points (birth and 9 years), children included in
the study did not differ from all children in the cohort by other
demographic and exposure variables (e.g., poverty level, mar-
riage status, type of work during pregnancy, alcohol and smok-
ing intake during pregnancy, prenatal exposure to DDT/DDE
and PBDEs). Study protocols (2010-01-620 and 2010-03-949) were
approved by the University of California, Berkeley Committee
for Protection of Human Subjects. Written informed consent
was obtained from all mothers, and assent was provided by the
children at the 9-year assessment.
Blood Collection and Processing
Blood specimens were collected from the umbilical cords of
CHAMACOS children after delivery and by venipuncture when
children were approximately 9 years old. Heparinized whole
blood was collected in BD vacutainersVR (Becton, Dickinson and
Company, Franklin Lakes, NJ), centrifuged, divided into plasma,
buffy coats and red blood cells, and stored at 80C at the
School of Public Health Biorepository, University of California,
Berkeley. Stringent conditions in accordance with the Best
Practices for Biorepositories were followed [43].
Determination of PON1 Genotypes
DNA was isolated from blood clots as described previously [24].
In total, 39 genetic variants in PON1 and 2 SNPS each in PON2
and PON3 were genotyped. The promoter SNP, PON1-108, was
genotyped using a fluorogenic allele-specific assay (Amplifluor,
Chemicon, Temecula, CA). It required a two-part nested poly-
merase chain reaction strategy, in which the region surrounding
the SNP was pre-amplified using non-allelic flanking primers
and then the amplicon was diluted and used as the template for
the Amplifluor assay. The coding polymorphisms, PON1192 and
PON155, as well as promoter SNP, PON1-162, were genotyped using
the Taqman real-time polymerase chain reaction method.
Briefly, primers for the nucleotide sequence flanking the SNP
and probes specific for the SNP were custom designed by
Applied Biosystems, Inc. (Foster City, CA). The remaining 39
SNPs and indels were genotyped using the multiplex platform
iPlex (Sequenom, San Diego, CA). Quality assurance procedures
for genotyping of these PON1 SNPs included assessment of ran-
domly distributed blank samples in each plate and duplicates of
randomly selected samples with independently isolated DNA
from the same subjects. Repeated analysis (4% of samples) in
several runs showed a high degree (>99%) of concordance. All
discrepancies were resolved with additional genotyping.
Determination of PON1 AREase Activity Levels
AREase activity in plasma samples was measured by determin-
ing the rate of phenyl acetate hydrolysis using spectrophoto-
metric methods as described previously [44]. A strong
correlation (r> 0.85) between measured PON1 quantity and
AREase activity have been demonstrated by ELISA and Western
blot-based methods utilizing PON1 antibodies [45, 46], making
the AREase assay a reliable measure of PON1 enzyme quantity.
All assays were performed in triplicate. Quality assurance in-
cluded use of internal controls (aliquots of the same sample run
on all assay plates), assessment of repeat samples (separate ali-
quots of the same sample run on different days), and concur-
rent analyses of specimens from different collections (samples
from different time points run on the same plates) [47]. The
average coefficient of variation (CV) for repeated samples was
8.5% and the correlation coefficient between repeated runs was
0.94. The average CV for internal controls samples, a measure of
inter-assay variability, was 8.7%.
Bisulfite Treatment and Methylation Analyses
DNA was previously isolated from clots using a QIAamp Blood
DNA Maxi kit (Qiagen, Inc., Santa Clarita, CA), normalized to
55 mg/ml. Zymo Bisulfite conversion Kits (Zymo Research,
Orange, CA) were used to bisulfite convert 1ug aliquots of DNA.
Methylation levels at 18 PON1 CpG sites were analyzed as part
of a genome-wide methylation assessment using the Illumina
Infinium 450k DNA methylation BeadChip. DNA samples were
whole-genome amplified, enzymatically fragmented, purified,
and applied to the Infinium 450k BeadChips according to the
Illumina methylation protocol [48, 49]. BeadChip processing was
performed using robotics, and the Illumina Hi-Scan system was
used for analysis. Samples included in the analysis had detec-
tion P values below 0.01 for 95% of CpG sites. Poor performing
CpG sites with P value> 0.01 were excluded. Two PON1 CpG sites
mapping to SNPs in the Illumina annotation were also excluded
resulting in a total of 16 PON1 CpGs that were included in the
subsequent analyses. Raw signal intensities were background
corrected and then normalized for color-channel bias using the
all sample mean normalization method as described previously
by Yousefi et al. [50]. We also applied a second normalization al-
gorithm, beta mixture quantile normalization, to make interpre-
tation between type I and type II probes comparable [51].
Methylation data were expressed as M values, which are calcu-
lated as the log2 ratio of the intensities of methylated probe to
unmethylated probe [52]. Negative M values therefore indicate
that the unmethylated form of a CpG site is more abundant
than the methylated form.
Stringent quality control criteria were applied for handling
of all samples and DNA methylation data. The quality assur-
ance procedures included use of repeats and internal standards
to minimize technical variability. Additionally, samples from
both age groups were randomly distributed among different
BeadChips to minimize experimental bias and batch effects.
Differential Cell Count
To examine the relationship of blood cell composition with
DNA methylation in PON1 CpG sites, we performed differential
cell counts in a subset of umbilical cord blood samples (n¼ 82)
as described previously [53]. To prepare heparinized whole
blood smears, we used the “gold standard” Wright-Push blood
smearing technique [54] followed by staining utilizing a
DiffQuikVR staining kit. Slides were fixed for 15 minutes at 23C
and were then stained in basophilic dye and eosinophilic dye
for 5 seconds each and washed after each staining period. Slides
were scored under light microscopy (Zeiss Axioplan) with a
magnification lens of 1000x and oil immersion. At least 100 cells
were scored for each slide, and a percentage of each cell type
(lymphocytes, monocytes, neutrophils, eosinophils, and baso-
phils) was used for data analysis. To ensure consistency and re-
producibility of scoring, 100 cells were scored in sets of 3
(3*100¼ 300) for a subset of 35 samples. The CV for the repeat
scoring in this subset was less than 10%.
Minfi Cell Count Estimation
Whole blood smears were not available for differential cell
count in 9-year-old CHAMACOS children. Instead for these
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children, we used the Bioconductor R package minfi (v1.10.2) [55]
to estimate the distribution of six (CD8þ T and CD4þ T lympho-
cytes, CD56þ natural killer cells, CD19þ B cells, CD14þ mono-
cytes, and granulocytes) different white blood cell types based
on their methylation signatures in 450K data. We did not use
minfi estimates for cell composition in cord blood samples be-
cause as we recently described in Yousefi et al. [53] In Press, pro-
portions of white blood cells in newborns are significantly
different from the adult reference samples on which minfi esti-
mates are based [56, 57]. We also found that unlike newborns,
minfi estimates of cell composition in older children were much
more comparable to those determined by differential cell count.
This corresponds with published age-specific reference values
[56, 57], which show that compared with adults, blood cell com-
position in newborns and young children is quite different but
begin to resemble adult levels by ages 9–12 years. For compari-
son of cell type composition in cord bloods to those estimated
by minfi in 9-year-old bloods, we use proportions of lympho-
cytes, granulocytes, and monocytes. For minfi estimates, this re-
quired summation of the frequencies for CD8þ T, CD4þ T,
natural killer cells, and B cells to calculate the proportion of
lymphocytes. For differential cell count, proportions of neutro-
phils, eosinophils, and basophils were summed to give an esti-
mate of granulocytes.
Statistical Analysis
We used generalized estimating equations to determine the as-
sociation of age with methylation levels at PON1 CpG, adjusting
for batch (coded as categorical variable) and cell composition.
For cell composition, we included proportion of monocytes and
granulocytes in the model, using the proportion of lymphocytes
as baseline.
Correlations of methylation levels at different CpG sites
were determined by calculation of Pearson’s correlation coeffi-
cients (r). LD methylation blocks were established based on sev-
eral criteria slightly modified from Shoemaker et al. [12] and Liu
et al. [11]: (i) they had to contain at least 3 contiguous CpG sites
and (ii) at least 50% of the CpG site pairs had to have methyla-
tion levels that were highly correlated with each other (r2> 0.4).
To determine the relationship between genetic polymor-
phisms and methylation, we constructed linear regression mod-
els where genotype expressed as the number of minor alleles
(0, 1, or 2) was the independent variable and the methylation
at each CpG site (expressed as M values) was the outcome.
Models were also adjusted for batch (coded as a categorical vari-
able). A separate model was run for each individual CpG site.
Bonferonni correction was used to account for multiple testing.
As there were 16 CpG sites, 3 genetic polymorphisms (PON1-108,
PON1192, and PON155), and 2 ages comprising 96 tests, we used
an adjusted type I error rate of 0.05/96¼ 5.21 E-04. We repeated
these models in a subset of newborns (n¼ 83) who also had dif-
ferential cell counts available to adjust for cell type distribution.
In these models, we included percent lymphocytes, monocytes,
basophils, and eosinophils in the models and used the percent
neutrophils as the baseline. Similar models were also per-
formed for 9-year olds using minfi estimates of cell composition
(n¼ 218).
We also used linear regression models to examine associa-
tions between methylation and AREase activity. We constructed
models including methylation at a single CpG site and batch as
the independent variables and AREase as the dependent vari-
able. Using Bonferonni correction, we considered P values less
than 1.6 E-03 (0.05/32 tests) to be statistically significant. In
addition to constructing separate models for each individual
CpG site, we also used principal component (PC) analysis to
summarize methylation at Block 1 and in the outer cluster of
CpG sites (Fig. 2). The PCs explaining 95% of the variance of
methylation for each group of CpG sites were incorporated as
variables in regression models of AREase activity (dependent
variable).
Recent studies examining mediation of the relation of ge-
netic polymorphisms on gene expression by epigenetics have
employed causal inference methodologies [58–60]. We used the
PARAMED module in STATA [32, 33] to determine the extent to
which PON1 methylation mediates the effect of PON1-108 geno-
type on AREase activity. The methodologies applied in this
module rely on a counterfactual framework based on paramet-
ric regression modelling and can estimate the natural direct ef-
fect and natural indirect effect (NIE) in the presence of
exposure-mediator interaction. All analyses were performed in
STATA (version 12.0; StataCorp, College Station, TX) and R (ver-
sion 3.1.2; R Development Core Team 2008).
Conflict of interest: None declared.
Acknowledgements
We are grateful to the laboratory and field staff and partici-
pants of the CHAMACOS study for their contributions. We
are especially thankful to Dr Lisa Barcellos and Ms Hong
Quach for their help with the Illumina 450K methylation as-
say, and Michael Ha and Girish Motwani who helped with
differential cell counts in this study. This work was sup-
ported by grants from the National Institute of
Environmental Health Science (NIEHS) [PO1 ES009605,
R01ES023067] and from the US Environmental Protection
Agency (EPA) [RD83451301, R82670901]. Its contents are
solely the responsibility of the authors and do not necessar-
ily represent the official views of NIEHS or EPA.
Data availability
Data available in Supplementary Material.
Supplementary data
Supplementary data is available at EnvEpig online.
References
1. Tammen SA, Friso S, Choi SW. Epigenetics: the link between
nature and nurture. Mol Aspects Med 2013;34:753–64.
2. Schubeler D. Function and information content of DNA meth-
ylation. Nature 2015;517:321–6.
3. Robertson KD. DNA methylation and human disease. Nat Rev
Genet 2005;6:597–610.
4. Tammen SA, Friso S, Choi SW. Epigenetics: the link between
nature and nurture. Mol Aspects Med 2012;34:753–764.
5. Waterland RA. Is epigenetics an important link between early
life events and adult disease? Horm Res 2009;71(Suppl 1):13–6.
6. Bailey KA, Wu MC, Ward WO et al. Arsenic and the epige-
nome: interindividual differences in arsenic metabolism re-
lated to distinct patterns of DNA methylation. J Biochem Mol
Toxicol 2013;27:106–15.
7. De Jager PL, Srivastava G, Lunnon K et al. Alzheimer’s disease:
early alterations in brain DNA methylation at ANK1, BIN1,
RHBDF2 and other loci. Nat Neurosci 2014;17:1156–63.
PON1 epigenetics | 9
8. Joubert BR, Haberg SE, Nilsen RM et al. 450K epigenome-wide
scan identifies differential DNA methylation in newborns re-
lated to maternal smoking during pregnancy. Environ Health
Perspect 2012;120:1425–31.
9. Swan EJ, Maxwell AP, McKnight AJ. Distinct methylation pat-
terns in genes that affect mitochondrial function are associ-
ated with kidney disease in blood-derived DNA from
individuals with type 1 diabetes. Diabet Med 2015;32:1110–
1115.
10.Gabriel SB, Schaffner SF, Nguyen H et al. The structure of
haplotype blocks in the human genome. Science
2002;296:2225–9.
11.Liu Y, Li X, Aryee MJ, Ekstrom TJ et al. GeMes, clusters of
DNA methylation under genetic control, can inform genetic
and epigenetic analysis of disease. Am J Hum Genet 2014;94:
485–95.
12.Shoemaker R, Deng J, Wang W et al. Allele-specific methyla-
tion is prevalent and is contributed by CpG-SNPs in the hu-
man genome. Genome Res 2010;20:883–9.
13.Huang YT. Integrative modeling of multiple genomic data
from different types of genetic association studies.
Biostatistics 2014;15:587–602.
14.Kundaje A, Meuleman W, Ernst J et al. Integrative analy-
sis of 111 reference human epigenomes. Nature
2015;518:317–30.
15.Li HL, Liu DP, Liang CC. Paraoxonase gene polymorphisms,
oxidative stress, and diseases. J Mol Med 2003;81:766–79.
16.Harley KG, Huen K, Schall RA et al. Association of organo-
phosphate pesticide exposure and paraoxonase with birth
outcome in Mexican-American women. PLoS One 2011;6:
e23923.
17. Infante-Rivard C. Genetic association between single nucleo-
tide polymorphisms in the paraoxonase 1 (PON1) gene and
small-for-gestational-age birth in related and unrelated sub-
jects. Am J Epidemiol 2010;171:999–1006.
18.Lawlor DA, Day IN, Gaunt TR et al. The association of
the paraoxonase (PON1) Q192R polymorphism with depres-
sion in older women: findings from the British Women’s
Heart and Health Study. J Epidemiol Community Health
2007;61:85–7.
19.Leduc V, Poirier J. Polymorphisms at the paraoxonase 1 L55M
and Q192R loci affect the pathophysiology of Alzheimer’s dis-
ease: emphasis on the cholinergic system and beta-amyloid
levels. Neurodegener Dis 2008;5:225–7.
20.Ryckman KK, Morken NH, White MJ et al. Maternal and fetal
genetic associations of PTGER3 and PON1 with preterm birth.
PLoS One 2010;5:e9040.
21.Eskenazi B, Huen K, Marks A et al. PON1 and neurodevelop-
ment in children from the CHAMACOS study exposed to or-
ganophosphate pesticides in utero. Environ Health Perspect
2010;118:1775–81.
22.Eskenazi B, Kogut K, Huen K et al. Organophosphate pesticide
exposure, PON1, and neurodevelopment in school-age
children from the CHAMACOS study. Environ Res 2014;134C:
149–57.
23.Furlong CE, Holland N, Richter RJ et al. PON1 status of
farmworker mothers and children as a predictor of organo-
phosphate sensitivity. Pharmacogenet Genomics 2006;16:
183–90.
24.Holland N, Furlong C, Bastaki M et al. Paraoxonase polymor-
phisms, haplotypes, and enzyme activity in Latino mothers
and newborns. Environ Health Perspect 2006;114:985–91.
25.Liu ME, Liao YC, Lin RT et al. A functional polymorphism of
PON1 interferes with microRNA binding to increase the risk
of ischemic stroke and carotid atherosclerosis. Atherosclerosis
2013;228:161–7.
26.Holland N, Lizarraga D, Huen K. Recent progress in the
genetics and epigenetics of paraoxonase: why it is relevant to
children’s environmental health. Curr Opin Pediatr 2015;27:
240–7.
27.Schrader C, Rimbach G. Determinants of paraoxonase 1
status: genes, drugs and nutrition. Curr Med Chem 2011;18:
5624–43.
28.de la Iglesia RMM, Sa´nchez-Muniz FJ, Zulet MA et al.
Arylesterase activity is associated with antioxidant intake
and paraoxonase-1 (pon1) gene methylation in metabolic
syndrome patients following an energy restricted diet. EXCLI
J 2014;13:416–26.
29.Carlson CS, Heagerty PJ, Hatsukami TS et al. TagSNP analyses
of the PON gene cluster: effects on PON1 activity, LDL
oxidative susceptibility, and vascular disease. J Lipid Res 2006;47:
1014–24.
30.Deakin S, Leviev I, Brulhart-Meynet MC et al. Paraoxonase-1
promoter haplotypes and serum paraoxonase: a predomi-
nant role for polymorphic position - 107, implicating the Sp1
transcription factor. Biochem J 2003;372:643–9.
31.Huen K, Barcellos L, Beckman K et al. Effects of PON polymor-
phisms and haplotypes on molecular phenotype in Mexican-
American mothers and children. Environ Mol Mutagen
2011;52:105–16.
32.Emsley R, Liu H, Dunn G et al. PARAMED: stata module to per-
form causal mediation analysis using parametric regression
models 2013. Available: https://ideas.repec.org/c/boc/bocode/
s457581.html (4 March 2015, date last accessed).
33.Valeri L, Vanderweele TJ. Mediation analysis allowing for ex-
posure-mediator interactions and causal interpretation: the-
oretical assumptions and implementation with SAS and SPSS
macros. Psychol Methods 2013;18:137–50.
34.Bonder MJ, Kasela S, Kals M et al. Genetic and epigenetic regu-
lation of gene expression in fetal and adult human livers.
BMC Genomics 2014;15:860.
35.Schalkwyk LC, Meaburn EL, Smith R et al. Allelic skewing of
DNA methylation is widespread across the genome. Am J
Hum Genet 2010;86:196–212.
36.Gertz J, Varley KE, Reddy TE et al. Analysis of DNA methyla-
tion in a three-generation family reveals widespread ge-
netic influence on epigenetic regulation. PLoS Genet 2011;7:
e1002228.
37.Meaburn EL, Schalkwyk LC, Mill J. Allele-specific methylation
in the human genome: implications for genetic studies of
complex disease. Epigenetics 2010;5:578–82.
38.Blattler A, Farnham PJ. Cross-talk between site-specific tran-
scription factors and DNA methylation states. J Biol Chem
2013;288:34287–94.
39.Osaki F, Ikeda Y, Suehiro T et al. Roles of Sp1 and protein ki-
nase C in regulation of human serum paraoxonase 1 (PON1)
gene transcription in HepG2 cells. Atherosclerosis 2004;176:
279–287.
40.Holler M, Westin G, Jiricny J et al. Sp1 transcription factor
binds DNA and activates transcription even when the binding
site is CpG methylated. Genes Dev 1988;2:1127–35.
41.Costa LG, Giordano G, Furlong CE. Pharmacological
and dietary modulators of paraoxonase 1 (PON1) activity and
expression: the hunt goes on. Biochem Pharmacol 2011;81:
337–44.
42.Eskenazi B, Bradman A, Gladstone E et al. CHAMACOS, a lon-
gitudinal birth cohort study: lessons from the fields.
J Childrens Health 2003;1:3–27.
10 | Environmental Epigenetics, 2015, Vol. 1, No. 1
43. ISBER. 2012 best practices for repositories: collection, storage,
retrieval, and distribution of biological materials for research.
Biopreserv Biobank 2012;10:79–161.
44.Richter RJ, Furlong CE. Determination of paraoxonase (PON1)
status requires more than genotyping. Pharmacogenetics
1999;9:745–53.
45.Connelly PW, Maguire GF, Picardo CM et al. Development
of an immunoblot assay with infrared fluorescence to quan-
tify paraoxonase 1 in serum and plasma. J Lipid Res 2008;49:
245–50.
46.Kujiraoka T, Oka T, Ishihara M et al. A sandwich enzyme-
linked immunosorbent assay for human serum paraoxonase
concentration. J Lipid Res 2000;41:1358–63.
47.Huen K, Richter R, Furlong C et al. Validation of PON1 enzyme
activity assays for longitudinal studies. Clin Chim Acta
2009;402:67–74.
48.Bibikova M, Barnes B, Tsan C et al. High density DNA methyl-
ation array with single CpG site resolution. Genomics
2011;98:288–95.
49.Sandoval J, Heyn H, Moran S et al. Validation of a DNA meth-
ylation microarray for 450,000 CpG sites in the human ge-
nome. Epigenetics 2011;6:692–702.
50.Yousefi P, Huen K, Schall RA et al. Considerations for
normalization of DNA methylation data by Illumina 450K
BeadChip assay in population studies. Epigenetics 2013;8:
1141–52.
51.Teschendorff AE, Marabita F, Lechner M et al. A beta-mixture
quantile normalization method for correcting probe design
bias in Illumina Infinium 450 k DNA methylation data.
Bioinformatics 2013;29:189–96.
52.Du P, Zhang X, Huang CC et al. Comparison of Beta-value and
M-value methods for quantifying methylation levels by mi-
croarray analysis. BMC Bioinformatics 2010;11:587.
53.Yousefi P, Huen K, Quach H, Motwani G, Hubbard A, Eskenazi
B, Holland N. Estimation of blood cellular heterogeneity in
newborns and children for epigenome-wide association stud-
ies. Environ Mol Mutagen. In Press.
54.Houwen B. The differential cell count. Lab Hematol 2001;7:
89–100.
55.Aryee MJ, Jaffe AE, Corrada-Bravo H et al. Minfi: a flexible and
comprehensive bioconductor package for the analysis of
Infinium DNA methylation microarrays. Bioinformatics
2014;30:1363–9.
56.Dallman P. Blood and blood-forming tissues. In: A Rudolph
(ed.), Paediatrics. New York: Appleton-Century-Crofts, 1977,
1109–12.
57.Nathan D, Oski F, Orkin S. Nathan and Oski’s Hematology of
Infancy and Childhood, Vol. 2, 6 edn. Philadelphia, PA:
Saunders, 2003.
58.Huang YT. Integrative modeling of multi-platform genomic
data under the framework of mediation analysis. Stat Med
2015;34:162–78.
59.Koestler DC, Chalise P, Cicek MS et al. Integrative
genomic analysis identifies epigenetic marks that mediate
genetic risk for epithelial ovarian cancer. BMC Med Genomics
2014;7:8.
60.Liu Y, Aryee MJ, Padyukov L et al. Epigenome-wide associa-
tion data implicate DNA methylation as an intermediary of
genetic risk in rheumatoid arthritis. Nat Biotechnol 2013;31:
142–7.
PON1 epigenetics | 11
